Slingshot members are tracking this event:
Teva to complete phase 3 trial for SD-809 as a treatment for Chorea Associated With Huntington Disease in December 2015 (via Aspex acquisition)
Slingshot Insights Explained
Apr 18, 2016
Don’t see a project related to the catalyst you care about?
Related Keywords Sd-809, Chorea Associated With Huntington Disease, Phase Iii